Enzyme, Phase II detoxification enzyme, Glutathione S-transferase family (Alpha class)
01
Overview
Glutathione S-transferase alpha 2 (GSTA2) is an enzyme belonging to the alpha class of the glutathione S-transferase family, predominantly expressed in the liver and involved in cellular defense against toxins and oxidative stress by catalyzing the conjugation of glutathione to a broad range of electrophilic compounds. GSTA2 expression is regulated by genetic polymorphisms and stress-responsive factors, and it contributes to detoxification processes, antioxidant defense, and the regulation of cell survival and apoptotic pathways. It plays roles in cancer progression, particularly hepatocellular carcinoma, and in protection against neurodegenerative and oxidative injuries, making it both a promising therapeutic target and a disease biomarker[1][2][3][4][5].
Other names
GSTA2GST2GSTA2-2GTA2GTH2GST HA subunit 2GST class-alpha member 2GST-gammaS-(hydroxyalkyl)glutathione lyase A2glutathione S-alkyltransferase A2glutathione S-aralkyltransferase A2glutathione S-aryltransferase A2liver GST2testis tissue sperm-binding protein Li 59n
02
Mechanism of action
GSTA2's mechanism of action primarily involves the conjugation of glutathione to electrophilic substrates, serving as a key enzyme in phase II metabolism. It also contributes to the reduction of reactive oxygen species and peroxidation damage through its glutathione peroxidase activity, and has been shown to inhibit apoptosis in various cellular models, including cancer and neuronal cells.
03
Biological functions
Detoxification of electrophilic compounds (including carcinogens, drugs, toxins, products of oxidative stress)Glutathione-mediated conjugation and peroxidase activityAntioxidant defense and protection from reactive oxygen speciesRegulation of cellular signaling pathways such as MAPK, JNK, AKT, and NF-κB in the context of oxidative stress and cell survival
04
Disease associations
Cancer (notably hepatocellular carcinoma, colorectal cancer, lung cancer)Neurodegenerative disease (Parkinson’s disease, ischemic/oxidative neural injury)Other roles in ischemia-reperfusion injury and liver diseases
05
Safety considerations
Non-specific tissue targeting in protein-based therapies (noted for fusion proteins like PEP-1-GSTA2)Potential for promoting cancer cell survival and metastasis, especially in HCC, when upregulated
06
Interacting drugs
Chemotherapeutic agents (generically; specific drugs not clearly listed in current results but known to metabolize or be substrates of GSTs)
2 more in the full profile.
07
Biomarkers
Circulating/early-phase GSTA2 as a prognostic biomarker for hepatocellular carcinoma recurrence following liver transplantationGSTA2 expression (mRNA/protein) as a marker of oxidative stress and disease prognosis (HCC, ischemia, PD)
Beyond the preview
Go deeper on Glutathione S-transferase alpha 2 (GSTA2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Drug pipeline
Explore the programs pursuing this target and their development progress.
Drug candidates
Developers
Development stage
Clinical trials
Follow the clinical studies evaluating therapies directed at this target.
Trial design
Status
Readouts
Competitive landscape
Compare approaches across drug candidates, modalities, and indications.
Programs
Modalities
Indications
Literature & evidence
Investigate the research and source evidence behind target biology and development.
Publications
Sources
Analysis
Patents
Explore patent activity around therapies and technologies addressing this target.
Patents
Assignees
Technologies
Research & analysis
Connect target biology, drug development, and emerging evidence in your research.
Biology
Development news
Analysis
Bring the full picture into focus.
See how Gosset can support your research on Glutathione S-transferase alpha 2 (GSTA2).